Quality of life in immunoglobulin A-nephropathy
https://doi.org/10.28996/2618-9801-2024-4-459-468
Abstract
Background: The quality of life (QoL) and the psychological burden of immunoglobulin A nephropathy (IgAN) have not been thoroughly studied.
Aim: To analyze QoL and complaints of patients with IgAN and to test the hypothesis that QoL scores are associated with clinical and demographic variables.
Patients and methods: The study included 221 patients with primary IgAN, confirmed by biopsy. None of patients had received immunosuppressive treatment. QOL was assessed using the Russian version of the Kidney Disease Quality of Life Short Form (KDQOL-SF) questionnaire, which includes general scales for measuring QoL independent of disease and kidney-specific scales. In additions to QoL parameters, the prevalence of patient complaints was examined. Routine clinical and demographic data were used as independent variables in multiple regression models.
Results: General QoL scores in patients with IgAN were comparable to those of conditionally healthy individuals. On CKD-specific scales, the highest scores were reported for "work status" and "symptoms/problems", while the lowest were for "burden of kidney disease". Key stressors included the disease itself, dietary restrictions, fatigue and impact of the disease on appearance. Female sex, older age, lower albumin level, and higher average blood pressure were independently associated with reduced QoL.
Conclusion: Although IgAN patients scored relatively high on most QoL scales, they endure a a significant psychological and social burden. Identifying and addressing the psychological and social factors influencing life under the strain of the disease can be crucial for for improving patient-centered outcomes in IgAN management.
Supporting agencies: The research was funded by the Russian Science Foundation (project No. 23 15 00510).
About the Authors
I. A. Vasilieva
Research Institute of Nephrology, Pavlov University
Russian Federation
Russian Federation
6–8, Lev Tolstoy str., 197022, Saint Petersburg
Z. Sh. Kochoyan
Research Institute of Nephrology, Pavlov University
Russian Federation
Russian Federation
6–8, Lev Tolstoy str., 197022, Saint Petersburg
E. N. Levykina
Research Institute of Nephrology, Pavlov University
Russian Federation
Russian Federation
6–8, Lev Tolstoy str., 197022, Saint Petersburg
V. A. Dobronravov
Research Institute of Nephrology, Pavlov University
Russian Federation
Russian Federation
6–8, Lev Tolstoy str., 197022, Saint Petersburg
References
1. Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018;38(5):435-442. DOI: 10.1016/j.semnephrol.2018.05.013
2. Hassler JR. IgA nephropathy: a brief review. Semin Diagn Pathol. 2020;37(3):143-147. DOI: 10.1053/j.semdp.2020.03.001
3. Zhao Y, Chen YP, Wu YQ et al. Effect of physical activity on depression symptoms in patients with IgA nephropathy. J Int Med Res. 2020;48(1):300060519898008. DOI: 10.1177/0300060519898008
4. Canetta PA, Troost JP, Mahoney S et al. Health-related quality of life in glomerular disease. Kidney Int. 2019;95(5):1209-1224. DOI: 10.1016/j.kint.2018.12.018
5. Marsh K, Ho KA, Lo R et al. Assessing Patient Preferences in Rare Diseases: Direct Preference Elicitation in the Rare Chronic Kidney Disease, Immunoglobulin A Nephropathy. Patient. 2021;14(6):837-847. DOI: 10.1007/s40271-021-00521-3
6. Vasilieva IА, Levykina EN, Dobronravov VА. Quality of life and associated clinical factors in immune-mediated glomerulopathies. Nephrology and Dialysis. 2023;25(4):541-553. DOI: 10.28996/2618-9801-2023-4-541-553 (In Russian)
7. Hays RD, Kallich JD, Mapes DL et al. Development of the kidney disease quality of life instrument. Qual Life Res. 1994;3(5):329-338. DOI: 10.1007/BF00451725
8. Vasilieva I.A. Validation of the Russian version of the Kidney Disease Quality of Life Short Form (KDQOL-SFTM) Instrument. Patient Reported Outcomes (PRO) Newsletter. 2006;36:14-15
9. Vasilieva IA. Russian version of the questionnaire the Kidney Disease and Quality of Life Short Form (KDQOLSFTM) a valuable diagnostic instrument for assessing quality of life of dialysis patients. Nephrology (Saint-Petersburg). 2007;11(1):64-70. DOI: 10.24884/1561-6274-2007-11-1-64-70 (In Russian)
10. Kwon CS, Daniele P, Forsythe A et al. A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy. J Health Econ Outcomes Res. 2021;8(2):36-45. DOI: 10.36469/001c.26129
11. Jhaveri KD, Bensink ME, Bunke M et al. Humanistic and Economic Burden of IgA Nephropathy: Systematic Literature Reviews and Narrative Synthesis. Pharmacoecon Open. 2023;7(5):709-722. DOI: 10.1007/s41669-023-00415-0
12. Zaidi O, Du F, Tang Z et al. Review on epidemiology, disease burden, and treatment patterns of IgA nephropathy in select APAC countries. BMC Nephrol. 2024;25(1):136. DOI: 10.1186/s12882-024-03555-5
13. Novik AA, Ionova TI. Rukovodstvo po issledovaniyu kachestva zhizni v medicine. 2 izd. M.: ZAO «OLMA Media Grupp», 2007. (In Russian)
14. Amirdjanova VN, Goryachev DV, Korshunov NI et al. SF-36 questionnaire population quality of life indices. Scientific and practical rheumatology. 2008. 46(1): 36-48. (In Russian)
15. Hsiung JT, Kleine CE, Naderi N et al. Association of Pre-End-Stage Renal Disease Serum Albumin With Post-EndStage Renal Disease Outcomes Among Patients Transitioning to Dialysis. J Ren Nutr. 2019;29(4):310-321. DOI: 10.1053/j.jrn.2018.09.004
16. Tyagi N, Chauhan J, George A et al. Patient insights for immunoglobulin A nephropathy (IgAN) Using Social Media Listening. Value in Health. 2019;22(Supplement 3):S919
Review
For citations:
Vasilieva I.A., Kochoyan Z.Sh., Levykina E.N., Dobronravov V.A. Quality of life in immunoglobulin A-nephropathy. Nephrology and Dialysis. 2024;26(4):459-468. (In Russ.) https://doi.org/10.28996/2618-9801-2024-4-459-468
Views:
244
Email this article 